In 2019, the Committee moved legislation to prevent brand drug companies from amassing superfluous patents around their products—a strategy that, as we’ve written before, is uniquely problematic in the United States.
On May 13, experts convened at AEI to discuss the United States’ fiscal trajectory: how we got here, where we’re going, and what we can do to reduce the burden of debt for future generations.
On December 22, 2017, President Donald Trump signed into law the Tax Cuts and Jobs Act (TCJA).
Fourteen years ago, Congress established a regulatory pathway for biosimilars, direct competitors to branded biologic drugs.
Insulin, a drug first developed more than 100 years ago, has experienced a surge in political interest in recent years following dramatic price hikes.
